GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death

Cancer Letters

Volumn 329, Issue 1, 2013, Pages 27-36

  Enzenmüller, Stefanie ^a   Gonzalez, Patrick ^a   Karpel Massler, Georg ^b   Debatin, Klaus Michael ^a   Fulda, Simone ^a,c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Betulinic acid; GDC 0941; Glioblastoma; PI3K

Indexed keywords

ANTINEOPLASTIC AGENT; B 10; CASPASE 3; CATHEPSIN B; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; PICTILISIB; PROTEIN BAX; REGULATOR PROTEIN; TRANSCRIPTION FACTOR EB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL COMPARTMENTALIZATION; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; GENE SILENCING; GLIOBLASTOMA; LYSOSOME MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATOR GENE; TRANSCRIPTION FACTOR EB GENE;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOBLASTOMA; HUMANS; INDAZOLES; INTRACELLULAR MEMBRANES; LYSOSOMES; MATRIX METALLOPROTEINASES; PERMEABILITY; SULFONAMIDES; TRITERPENES;

EID: 84871712573     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.007     Document Type: Article

References (26)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
2. McLendon R., Friedman A., Bigner D., VanMei E., Brat D., Mastrogianakis G., Olson J., Mikkelsen T., Lehman N., Aldape K., Yung W., Bogler O., Weinstein J., VandenBerg S., Berger M., Prados M., Muzny D., Morgan M., Scherer S., Sabo A., Nazareth L., Lewis L., Hall O., Zhu Y., Ren Y., Alvi O., Yao J., Hawes A., Jhangiani S., Fowler G., San Lucas A., Kovar C., Cree A., Dinh H., Santibanez J., Joshi V., Gonzalez-Garay M., Miller C., Milosavljevic A., Donehower L., Wheeler D., Gibbs R., Cibulskis K., Sougnez C., Fennell T., Mahan S., Wilkinson J., Ziaugra L., Onofrio R., Bloom T., Nicol R., Ardlie K., Baldwin J., Gabriel S., Lander E., Ding L., Fulton R., McLellan M., Wallis J., Larson D., Shi X., Abbott R., Fulton L., Chen K., Koboldt D., Wendl M., Meyer R., Tang Y., Lin L., Osborne J., Dunford-Shore B., Miner T., Delehaunty K., Markovic C., Swift G., Courtney W., Pohl C., Abbott S., Hawkins A., Leong S., Haipek C., Schmidt H., Wiechert M., Vickery T., Scott S., Dooling D., Chinwalla A., Weinstock G., Mardis E., Wilson R., Getz G., Winckler W., Verhaak R., Lawrence M., O'Kelly M., Robinson J., Alexe G., Beroukhim R., Carter S., Chiang D., Gould J., Gupta S., Korn J., Mermel C., Mesirov J., Monti S., Nguyen H., Parkin M., Reich M., Stransky N., Weir B., Garraway L., Golub T., Meyerson M., Chin L., Protopopov A., Zhang J., Perna I., Aronson S., Sathiamoorthy N., Ren G., Yao J., Wiedemeyer W., Kim H., Kong S., Xiao Y., Kohane I., Seidman J., Park P., Kucherlapati R., Laird P., Cope L., Herman J., Weisenberger D., Pan F., Van den Berg D., Van Neste L., Yi J., Schuebel K., Baylin S., Absher D., Li J., Southwick A., Brady S., Aggarwal A., Chung T., Sherlock G., Brooks J., Myers R., Spellman P., Purdom E., Jakkula L., Lapuk A., Marr H., Dorton S., Choi Y., Han J., Ray A., Wang V., Durinck S., Robinson M., Wang N., Vranizan K., Peng V., Van Name E., Fontenay G., Ngai J., Conboy J., Parvin B., Feiler H., Speed T., Gray J., Brennan C., Socci N., Olshen A., Taylor B., Lash A., Schultz N., Reva B., Antipin Y., Stukalov A., Gross B., Cerami E., Wang W., Qin L., Seshan V., Villafania L., Cavatore M., Borsu L., Viale A., Gerald W., Sander C., Ladanyi M., Perou C., Hayes D., Topal M., Hoadley K., Qi Y., Balu S., Shi Y., Wu J., Penny R., Bittner M., Shelton T., Lenkiewicz E., Morris S., Beasley D., Sanders S., Kahn A., Sfeir R., Chen J., Nassau D., Feng L., Hickey E., Barker A., Gerhard D., Vockley J., Compton C., Vaught J., Fielding P., Ferguson M., Schaefer C., Zhang J., Madhavan S., Buetow K., Collins F., Good P., Guyer M., Ozenberger B., Peterson J., Thomson E. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
3. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
4. Chakravarti A., Zhai G., Suzuki Y., Sarkesh S., Black P.M., Muzikansky A., Loeffler J.S. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 2004, 22:1926-1933.
5. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
6. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
7. Parcellier A., Tintignac L.A., Zhuravleva E., Hemmings B.A. PKB and the mitochondria: AKTing on apoptosis. Cell. Signal. 2008, 20:21-30.
8. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
9. Madge L.A., Li J.H., Choi J., Pober J.S. Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J. Biol. Chem. 2003, 278:21295-21306.
10. Sardiello M., Palmieri M., di Ronza A., Medina D.L., Valenza M., Gennarino V.A., Di Malta C., Donaudy F., Embrione V., Polishchuk R.S., Banfi S., Parenti G., Cattaneo E., Ballabio A. A gene network regulating lysosomal biogenesis and function. Science 2009, 325:473-477.
11. Settembre C., Di Malta C., Polito V.A., Garcia Arencibia M., Vetrini F., Erdin S., Erdin S.U., Huynh T., Medina D., Colella P., Sardiello M., Rubinsztein D.C., Ballabio A. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332:1429-1433.
12. Settembre C., Zoncu R., Medina D.L., Vetrini F., Erdin S., Huynh T., Ferron M., Karsenty G., Vellard M.C., Facchinetti V., Sabatini D.M., Ballabio A. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. Embo J. 2012, 31:1095-1108.
13. Boya P., Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27:6434-6451.
14. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 2005, 5:886-897.
15. Repnik U., Turk B. Lysosomal-mitochondrial cross-talk during cell death. Mitochondrion 2010, 10:662-669.
16. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
17. Opel D., Westhoff M.A., Bender A., Braun V., Debatin K.M., Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res. 2008, 68:6271-6280.
18. Westhoff M.A., Kandenwein J.A., Karl S., Vellanki S.H., Braun V., Eramo A., Antoniadis G., Debatin K.M., Fulda S. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 2009, 28:3586-3596.
19. Gonzalez P., Mader I., Tchoghandjian A., Enzenmuller S., Cristofanon S., Basit F., Debatin K.M., Fulda S. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ. 2012, 19:1337-1346.
20. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K.M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997, 57:3823-3829.
21. Hacker S., Dittrich A., Mohr A., Schweitzer T., Rutkowski S., Krauss J., Debatin K.M., Fulda S. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009, 28:3097-3110.
22. Opel D., Poremba C., Simon T., Debatin K.M., Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 2007, 67:735-745.
23. Klionsky D.J., Abeliovich H., Agostinis P., Agrawal D.K., Aliev G., Askew D.S., Baba M., Baehrecke E.H., Bahr B.A., Ballabio A., Bamber B.A., Bassham D.C., Bergamini E., Bi X., Biard-Piechaczyk M., Blum J.S., Bredesen D.E., Brodsky J.L., Brumell J.H., Brunk U.T., Bursch W., Camougrand N., Cebollero E., Cecconi F., Chen Y., Chin L.S., Choi A., Chu C.T., Chung J., Clarke P.G., Clark R.S., Clarke S.G., Clave C., Cleveland J.L., Codogno P., Colombo M.I., Coto-Montes A., Cregg J.M., Cuervo A.M., Debnath J., Demarchi F., Dennis P.B., Dennis P.A., Deretic V., Devenish R.J., Di Sano F., Dice J.F., Difiglia M., Dinesh-Kumar S., Distelhorst C.W., Djavaheri-Mergny M., Dorsey F.C., Droge W., Dron M., Dunn W.A., Duszenko M., Eissa N.T., Elazar Z., Esclatine A., Eskelinen E.L., Fesus L., Finley K.D., Fuentes J.M., Fueyo J., Fujisaki K., Galliot B., Gao F.B., Gewirtz D.A., Gibson S.B., Gohla A., Goldberg A.L., Gonzalez R., Gonzalez-Estevez C., Gorski S., Gottlieb R.A., Haussinger D., He Y.W., Heidenreich K., Hill J.A., Hoyer-Hansen M., Hu X., Huang W.P., Iwasaki A., Jaattela M., Jackson W.T., Jiang X., Jin S., Johansen T., Jung J.U., Kadowaki M., Kang C., Kelekar A., Kessel D.H., Kiel J.A., Kim H.P., Kimchi A., Kinsella T.J., Kiselyov K., Kitamoto K., Knecht E., Komatsu M., Kominami E., Kondo S., Kovacs A.L., Kroemer G., Kuan C.Y., Kumar R., Kundu M., Landry J., Laporte M., Le W., Lei H.Y., Lenardo M.J., Levine B., Lieberman A., Lim K.L., Lin F.C., Liou W., Liu L.F., Lopez-Berestein G., Lopez-Otin C., Lu B., Macleod K.F., Malorni W., Martinet W., Matsuoka K., Mautner J., Meijer A.J., Melendez A., Michels P., Miotto G., Mistiaen W.P., Mizushima N., Mograbi B., Monastyrska I., Moore M.N., Moreira P.I., Moriyasu Y., Motyl T., Munz C., Murphy L.O., Naqvi N.I., Neufeld T.P., Nishino I., Nixon R.A., Noda T., Nurnberg B., Ogawa M., Oleinick N.L., Olsen L.J., Ozpolat B., Paglin S., Palmer G.E., Papassideri I., Parkes M., Perlmutter D.H., Perry G., Piacentini M., Pinkas-Kramarski R., Prescott M., Proikas-Cezanne T., Raben N., Rami A., Reggiori F., Rohrer B., Rubinsztein D.C., Ryan K.M., Sadoshima J., Sakagami H., Sakai Y., Sandri M., Sasakawa C., Sass M., Schneider C., Seglen P.O., Seleverstov O., Settleman J., Shacka J.J., Shapiro I.M., Sibirny A., Silva-Zacarin E.C., Simon H.U., Simone C., Simonsen A., Smith M.A., Spanel-Borowski K., Srinivas V., Steeves M., Stenmark H., Stromhaug P.E., Subauste C.S., Sugimoto S., Sulzer D., Suzuki T., Swanson M.S., Tabas I., Takeshita F., Talbot N.J., Talloczy Z., Tanaka K., Tanida I., Taylor G.S., Taylor J.P., Terman A., Tettamanti G., Thompson C.B., Thumm M., Tolkovsky A.M., Tooze S.A., Truant R., Tumanovska L.V., Uchiyama Y., Ueno T., Uzcategui N.L., van der Klei I., Vaquero E.C., Vellai T., Vogel M.W., Wang H.G., Webster P., Wiley J.W., Xi Z., Xiao G., Yahalom J., Yang J.M., Yap G., Yin X.M., Yoshimori T., Yu L., Yue Z., Yuzaki M., Zabirnyk O., Zheng X., Zhu X., Deter R.L. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008, 4:151-175.
24. Degtyarev M., De Maziere A., Orr C., Lin J., Lee B.B., Tien J.Y., Prior W.W., van Dijk S., Wu H., Gray D.C., Davis D.P., Stern H.M., Murray L.J., Hoeflich K.P., Klumperman J., Friedman L.S., Lin K. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J. Cell Biol. 2008, 183:101-116.
25. Oberle C., Huai J., Reinheckel T., Tacke M., Rassner M., Ekert P.G., Buellesbach J., Borner C. Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes. Cell Death Differ. 2010, 17:1167-1178.
26. Shuttleworth S.J., Silva F.A., Cecil A.R., Tomassi C.D., Hill T.J., Raynaud F.I., Clarke P.A., Workman P. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr. Med. Chem. 2011, 18:2686-2714.